Publication: Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension.
Loading...
Identifiers
Date
2022-03-11
Authors
Guillen-Del-Castillo, Alfredo
Meseguer, Manuel López
Fonollosa-Pla, Vicent
Gimenez, Berta Sáez
Colunga-Argüelles, Dolores
Revilla-Lopez, Eva
Rubio-Rivas, Manuel
Ropero, Maria Jose Cristo
Argibay, Ana
Barbera, Joan Albert
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Nature Publishing Group
Metrics
Export
Abstract
To assess severity markers and outcomes of patients with systemic sclerosis (SSc) with or without pulmonary arterial hypertension (PAH-SSc/non-PAH-SSc), and the impact of interstitial lung disease (ILD) on PAH-SSc. Non-PAH-SSc patients from the Spanish SSc registry and PAH-SSc patients from the Spanish PAH registry were included. A total of 364 PAH-SSc and 1589 non-PAH-SSc patients were included. PAH-SSc patients had worse NYHA-functional class (NYHA-FC), worse forced vital capacity (FVC) (81.2 ± 20.6% vs 93.6 ± 20.6%, P
Description
MeSH Terms
Familial Primary Pulmonary Hypertension
Humans
Hypertension, Pulmonary
Lung Diseases, Interstitial
Pulmonary Arterial Hypertension
Scleroderma, Systemic
Humans
Hypertension, Pulmonary
Lung Diseases, Interstitial
Pulmonary Arterial Hypertension
Scleroderma, Systemic
DeCS Terms
Enfermedades pulmonares intersticiales
Hipertensión arterial pulmonar
Esclerodermia sistémica
Hipertensión pulmonar primaria
Hipertensión pulmonar
Hipertensión arterial pulmonar
Esclerodermia sistémica
Hipertensión pulmonar primaria
Hipertensión pulmonar
CIE Terms
Keywords
Citation
Guillén-Del-Castillo A, Meseguer ML, Fonollosa-Pla V, Giménez BS, Colunga-Argüelles D, et al. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension. Sci Rep. 2022 Mar 28;12(1):5289. doi: 10.1038/s41598-022-09353-z. Erratum in: Sci Rep. 2022 Jul 28;12(1):12947.